Literature DB >> 10608012

Human Aortic Vascular Smooth Muscle Cells Digest Extracellular Matrix by Elaboration of Plasminogen Activators: Implications for Atherogenesis.

.   

Abstract

Migration and proliferation of vascular smooth muscle cells (SMCs) are hallmarks of atherogenesis and restenosis after angioplasty. Digestion of surrounding extracellular matrix (ECM) may be a critical link. To determine whether invasion of ECM by human aortic SMCs (HASMCs) depends on proteolytic digestion mediated by the cells themselves, we characterized ECM digestion in terms of solubilization of 3H-proline--labeled ECM, produced by the use of rat aortic SMCs, by HASMCs under various conditions. Plasmin alone (10 µg/ml) digested 80% of ECM in 2 hours. HASMCs in 10% fetal bovine serum cultured on ECM that was not exposed to plasmin digested 48% of the ECM in 7 days. When HASMCs were cultured on plasmin-pretreated ECM, only 14% of the residual ECM was digested. Conditioned media or cells cultured on porous membrane 1 mm removed from the ECM had no effect. Baseline secretion of tissue-type plasminogen activator (t-PA) into the media by HASMCs averaged 3.9 ng/105 cells/24 hr and baseline secretion of type-1 plasminogen activator inhibitor (PAI-1) averaged 1300 ng/105 cells/24 hr. Thrombin (5 U/ml) increased t-PA antigen production by 184% without altering PAI-1 activity and increased ECM degradation by 43% in 7 days. Transforming growth factor-beta (TGF-beta) decreased t-PA antigen production, increased PAI-1 activity, and decreased ECM degradation. These results suggest that (1) HASMCs can digest naturally produced ECM; (2) plasminogen-dependent mechanisms requiring cell contact are important in the initiation of this phenomenon; and (3) thrombin in the vicinity of clots may modulate the fibrinolytic and proteolytic properties of SMC through t-PA after vascular injury.

Entities:  

Year:  1995        PMID: 10608012     DOI: 10.1007/bf01064377

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  26 in total

Review 1.  Type 1 plasminogen activator inhibitor.

Authors:  D J Loskutoff; M Sawdey; J Mimuro
Journal:  Prog Hemost Thromb       Date:  1989

2.  Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery.

Authors:  A W Clowes; M M Clowes; Y P Au; M A Reidy; D Belin
Journal:  Circ Res       Date:  1990-07       Impact factor: 17.367

3.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

4.  Role of plasminogen activator in degradation of extracellular matrix protein by live human alveolar macrophages.

Authors:  H A Chapman; J J Reilly; L Kobzik
Journal:  Am Rev Respir Dis       Date:  1988-02

5.  Binding of tissue plasminogen activator to cultured human endothelial cells.

Authors:  K A Hajjar; N M Hamel; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

6.  Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue.

Authors:  J C Kirchheimer; B R Binder; H G Remold
Journal:  J Immunol       Date:  1990-09-01       Impact factor: 5.422

7.  Identification and characterization of human endothelial cell membrane binding sites for tissue plasminogen activator and urokinase.

Authors:  K A Hajjar; N M Hamel
Journal:  J Biol Chem       Date:  1990-02-15       Impact factor: 5.157

8.  Binding of plasminogen to cultured human endothelial cells.

Authors:  K A Hajjar; P C Harpel; E A Jaffe; R L Nachman
Journal:  J Biol Chem       Date:  1986-09-05       Impact factor: 5.157

9.  Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.

Authors:  K A Hajjar
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

10.  Upregulation of urokinase receptor expression on migrating endothelial cells.

Authors:  M S Pepper; A P Sappino; R Stöcklin; R Montesano; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more
  2 in total

1.  Phosphorothioate Oligodeoxynucleotide Inhibition of Restenosis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

2.  Interleukin-4 Modulation of Platelet-Derived Growth Factor-Induced Smooth Muscle Cell Urokinase Plasminogen Activator.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.